These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15270913)

  • 1. Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: first-line treatment with rituximab.
    Lami MC; Vabres P; Dreyfus B; Germain T; Guillet G
    Br J Dermatol; 2004 Jul; 151(1):250-2. PubMed ID: 15270913
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
    Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
    J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
    [No Abstract]   [Full Text] [Related]  

  • 3. Skin lesions mimicking septic arthritis.
    Mittal S; Graham V
    J Fam Pract; 2006 Oct; 55(10):881-4. PubMed ID: 17014754
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiocentric NK/T-cell lymphoma mimicking pyoderma gangrenosum.
    Emanuel PO; Mercer SE
    Indian J Cancer; 2011; 48(1):113-5. PubMed ID: 21330754
    [No Abstract]   [Full Text] [Related]  

  • 6. [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma].
    Charavin-Cocuzza M; Templier I; Simon A; Salameire D; Cuchet E; Reymond JL; Beani JC; Leccia MT
    Ann Dermatol Venereol; 2008 Dec; 135(12):848-51. PubMed ID: 19084696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma clinically simulating pyoderma gangrenosum.
    Wang Y; Li T; Tu P; Wu LS; Zhu XJ
    Clin Exp Dermatol; 2009 Oct; 34(7):e261-2. PubMed ID: 19438529
    [No Abstract]   [Full Text] [Related]  

  • 8. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous B-cell lymphoma treated with rituximab infusions.
    Schneider LA
    Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
    [No Abstract]   [Full Text] [Related]  

  • 12. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C; Duval-Modeste AB; Courville P; Joly P
    Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
    Park MY; Jung HJ; Park JE; Kim YC
    Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma.
    Perez-Gala S; Delgado-Jimenez Y; Goiriz R; Fraga J; Garcia-Diez A; Fernandez-Herrera J
    Arch Dermatol; 2006 Nov; 142(11):1516-7. PubMed ID: 17116855
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.
    Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous B-cell lymphomas.
    Kempf W; Denisjuk N; Kerl K; Cozzio A; Sander C
    J Dtsch Dermatol Ges; 2012 Jan; 10(1):12-22; quiz 23. PubMed ID: 22212142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.